Miguel Izquierdo, MD

Clinical Development Oncology, Novartis, Basel, Switzerland, Switzerland

Novartis (Employment, Shareholder)

Presentation(s):

• Risk of Myasthenia Gravis with Tyrosine Kinase Inhibitors: A Disproportionality Analysis from Vigibase and AERS Databases

  Friday, August 26, 2022
  5:15 PM – 5:20 PM CEST